

### SPECIFICATION

Please delete the following paragraph beginning at page 1, line 5 and ending on line 9.

#### CROSS REFERENCE TO RELATED APPLICATIONS

~~This application is a continuation in part application of and claims priority to U.S. Patent Application Serial No. 10/224,268, entitled *Synthetic Heparin-Binding Growth Factor Analogs*, filed on August 20, 2002, and the specification thereof is incorporated herein by reference~~

Please replace the paragraph beginning on page 23 line 20 and ending on line 21 with the following amended paragraph

**Table 3** below summarizes the ~~biochemical~~ biochemical interactions of one BMP analog, B2A2, and the modulation of alkaline phosphatase, wherein modulation was monitored using C2C12 cells. Please replace the paragraph beginning on page 42 line 13 and ending on line 21 with the following amended paragraph.

A synthetic HBGF analog, F7A2, was synthesized by standard solid phase peptide synthesis methods. The amino acid sequences of F7A2 corresponding to regions Y and Z of formula II are identical to those of F2A3 described in Example 1. The amino acid sequence YNIMEIRTVAVGIVA (SEQ ID NO:11) of the two X region peptides corresponds to amino acids derived from the  $\beta$ -4 and  $\beta$ -5 region of FGF-7. The loop connecting the  $\beta$ 4- $\beta$ 5 strands of FGF-7 contribute to high affinity receptor binding and is critical for ~~KGFR~~ FGFR recognition, as determined in domain-swapping and site-directed mutagenesis experiments (Sher et al. Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol. Chem. 275:34881-34886 (2000)).